Literature DB >> 27118577

The benefits of newborn screening for cystic fibrosis: The Canadian experience.

D Y F Mak1, J Sykes2, A L Stephenson3, L C Lands4.   

Abstract

BACKGROUND: The impact of newborn screening (NBS) for cystic fibrosis (CF) on early indicators of long-term health was evaluated in the context of government-sponsored healthcare and access to current therapies.
METHODS: Using data from the Canadian CF Registry between 2008 and 2013, we compared the rates of respiratory infections and markers of nutritional status in those diagnosed through NBS to those who were diagnosed clinically within the same time period using Mann-Whitney and Fischer's exact test as appropriate.
RESULTS: The study included 303 subjects, 201 in the NBS group and 102 in the non-NBS group. NBS patients were diagnosed earlier and had their first clinic visit at a younger age. Pancreatic insufficiency was less common in NBS patients. The incidence of Pseudomonas aeruginosa and Staphylococcus aureus were lower in NBS patients. After adjusting for age at clinic visit, gender, pancreatic status, and Pseudomonas aeruginosa infection status, mean z-scores for weight-for-age and height-for-age were higher in NBS patients, with no differences in BMI-for-age.
CONCLUSIONS: NBS programs for CF lead to improved long-term health outcomes for the CF population.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Growth; Hospitalization; Infection; Newborn screening; Nutritional status

Mesh:

Year:  2016        PMID: 27118577     DOI: 10.1016/j.jcf.2016.04.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  12 in total

1.  Shining new light on newborn screening of cystic fibrosis in the province of Quebec.

Authors:  Léticia Khendek
Journal:  Can J Public Health       Date:  2017-09-14

2.  Predictive effects of low birth weight and small for gestational age status on respiratory and nutritional outcomes in cystic fibrosis.

Authors:  Samar E Atteih; Karen S Raraigh; Scott M Blackman; Garry R Cutting; Joseph M Collaco
Journal:  J Cyst Fibros       Date:  2020-02-12       Impact factor: 5.482

3.  Interventions for promoting participation in shared decision-making for children and adolescents with cystic fibrosis.

Authors:  Helen Malone; Susan Biggar; Sheila Javadpour; Zai Edworthy; Greg Sheaf; Imelda Coyne
Journal:  Cochrane Database Syst Rev       Date:  2019-05-23

4.  Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK CF registry-based study.

Authors:  Daniela K Schlüter; Kevin W Southern; Carol Dryden; Peter Diggle; David Taylor-Robinson
Journal:  Thorax       Date:  2019-11-26       Impact factor: 9.139

Review 5.  Inborn Errors of Metabolism in the Era of Untargeted Metabolomics and Lipidomics.

Authors:  Israa T Ismail; Megan R Showalter; Oliver Fiehn
Journal:  Metabolites       Date:  2019-10-21

6.  Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia.

Authors:  Graham Sinclair; Vanessa McMahon; Amy Schellenberg; Tanya N Nelson; Mark Chilvers; Hilary Vallance
Journal:  Int J Neonatal Screen       Date:  2020-06-02

7.  Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening.

Authors:  David J Sas; Felicity T Enders; Ramila A Mehta; Xiaojing Tang; Fang Zhao; Barbara M Seide; Dawn S Milliner; John C Lieske
Journal:  Kidney Int       Date:  2019-12-13       Impact factor: 18.998

8.  Identification of 22q11.2 deletion syndrome via newborn screening for severe combined immunodeficiency. Two years' experience in Catalonia (Spain).

Authors:  Andrea Martin-Nalda; Anna M Cueto-González; Ana Argudo-Ramírez; Jose L Marin-Soria; Monica Martinez-Gallo; Roger Colobran; Albert Plaja; Neus Castells; Jacques Riviere; Eduardo F Tizzano; Pere Soler-Palacin
Journal:  Mol Genet Genomic Med       Date:  2019-10-30       Impact factor: 2.183

9.  Standardised clinical data from patients with primary ciliary dyskinesia: FOLLOW-PCD.

Authors:  Myrofora Goutaki; Jean-François Papon; Mieke Boon; Carmen Casaulta; Ernst Eber; Estelle Escudier; Florian S Halbeisen; Amanda Harris; Claire Hogg; Isabelle Honore; Andreas Jung; Bulent Karadag; Cordula Koerner-Rettberg; Marie Legendre; Bernard Maitre; Kim G Nielsen; Bruna Rubbo; Nisreen Rumman; Lynne Schofield; Amelia Shoemark; Guillaume Thouvenin; Hannah Willkins; Jane S Lucas; Claudia E Kuehni
Journal:  ERJ Open Res       Date:  2020-02-10

Review 10.  The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery.

Authors:  Virginie Scotet; Carine L'Hostis; Claude Férec
Journal:  Genes (Basel)       Date:  2020-05-26       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.